Article Text
Statistics from Altmetric.com
Q In diabetic patients with peripheral arterial occlusive disease (PAOD), is dalteparin more effective than placebo for improving chronic foot ulcers?
Clinical impact ratings Endocrine ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial.
Allocation:
concealed.*
Blinding:
blinded (patients and healthcare providers).*
Follow up period:
6 months.
Setting:
4 hospitals in Sweden.
Patients:
87 diabetic patients (mean age 72.5 y, 71% men) with PAOD, chronic foot ulcers (Wagner classification ulcer stage I and II) with duration >2 months; toe blood pressure (TBP) to arm blood pressure index ⩽0.6; and a daily dose of aspirin, 75 mg, for ⩾4 weeks. Exclusion criteria included vascular reconstruction or angioplasty in previous 3 months, renal insufficiency (serum creatinine ⩾200 µmol/l), and anticoagulants. All patients continued to receive aspirin.
Intervention
patients were stratified …
Linked Articles
- Glossary